Laboratory techniques in the diagnosis and assessment of hepatitis B virus infection

J J Gray, T G Wreghitt

Introduction
The discovery of Australia antigen (hepatitis B surface antigen (HBsAg)) by Blumberg in 1965,1 its association with serum hepatitis described by Prince in 1968 and the visualisation of the 42 nm infectious hepatitis B virus (HBV) particle by electron microscopy in 19702 led to research into the aetiology, treatment and prevention of serum hepatitis. Further serological markers of HBV and its mode of replication have been described,3,4 the HBV genome5 cloned6 and effective vaccines produced.7

HBV infection is endemic in certain geographical areas with approximately 300 million HBsAg carriers worldwide. The carrier rate varies from country to country with 0-2-0-5% in Western Europe and 8-20% in South East Asia. Rates are generally higher in the tropics, amongst males and in urban communities.

HBV infection may be symptomatic or asymptomatic and is associated with a wide spectrum of inflammatory liver disease. This ranges from acute to chronic hepatitis and may ultimately lead to cirrhosis or primary hepatocellular carcinoma. In acute symptomatic infections, patients may present with malaise, lethargy, anorexia, headache, mild diarrhoea or upper right quadrant pain followed by jaundice and arthralgia.

The detection of HBV markers in the serum of patients with HBV infection is not only important for diagnosis but also for management and predicting the outcome of infection.

Hepatitis B markers
HBsAg may be detected in the blood 2 to 8 weeks before the onset of hepatitis and persists during the acute phase. It is usually cleared from the bloodstream during the convalescence period when antibodies to hepatitis B surface antigen (anti-HBs) become detectable. Failure to clear HBsAg within six months usually indicates a chronic HBsAg carrier state although HBsAg may be present in some acute cases for up to 12 months. Hepatitis B core antigen (HBcAg) is not detected in the serum or plasma although a soluble component of the core protein, HBeAg, may be found a few days after the appearance of HBsAg. HBV DNA and DNA polymerase are also detected at this time and their presence, like that of HBeAg, indicates high infectivity. In an uncomplicated acute HBV infection HBeAg is usually cleared from the serum or plasma within 6 weeks but as with HBsAg it may persist in the carrier state.

The immune response to HBV infection is characterised in the first instance by the appearance of IgM antibodies to HBcAg (anti-HBc IgM) followed by anti-HBc IgG which may persist for life. As anti-HBc is not a neutralising antibody its presence does not preclude active viral replication nor the presence of infectious virus in the blood. However, the presence of antibody to hepatitis B antigen (anti-HBc), which appears after anti-HBc and is also a non-neutralising antibody, usually correlates with a reduction in viral replication and the resolution of abnormal liver function in an acute resolving infection. Anti-HBc may persist for several months but eventually is undetectable in serum or plasma. HBV mutants, defective in the expression of the pre-core region of the C gene, necessary for excretion of HBeAg, have been associated with chronic anti-HBc positive hepatitis B (HBeAg minus mutant).8 Anti-HBs is a neutralising antibody and its presence indicates recovery from infection and protection against reinfection. It is also produced in response to vaccination with plasma-derived or recombinant HBV vaccines. Therefore, the detection of anti-HBs in the absence of all other HBV markers indicates a response to vaccination.

Antigen expression may be prolonged and the production of antibodies to these antigens delayed in chronic HBV infection. Table 1 describes the interpretation of the serological markers detected after acute and chronic HBV infection and figure 1 demonstrates the relative concentrations of these serological markers.

Table 1  Serological markers in hepatitis B virus infection

<table>
<thead>
<tr>
<th>Marker</th>
<th>HBsAg</th>
<th>HBeAg</th>
<th>Anti-HBs</th>
<th>Anti-HBc</th>
<th>Anti-HBs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incubation period</td>
<td>+</td>
<td>+</td>
<td>+/-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acute infection</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Convalescence</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>History of past infection</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>History of vaccination</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Carrier state (high infectivity)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Carrier state (low infectivity)</td>
<td>+/-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>
In RPH anti-HBs is coupled to red blood cells in the presence of chronic chloride or tannic acid. The resulting anti-HBs-coupled red blood cells, which are agglutinated in the presence of HBsAg, are stable and may be freeze-dried (fig 2). Although RPH is a rapid and simple assay to perform it is prone to false-positive reactions. For this reason, control cells, prepared by coupling an anti-HBs negative immunoglobulin, derived from the same species, to red blood cells, should always be tested in parallel with the anti-HBs-coupled red blood cells. The sensitivity of RPH may vary from 5–50 ng HBsAg/ml serum.

RIAs, ELISAs and assays employing enhanced chemiluminescence capture HBsAg from the serum or plasma by means of anti-HBs bound to a solid phase. Captured HBsAg is then detected with a second antibody, labelled with a radioisotope in RIAs or an enzyme in ELISAs or chemiluminescent assays (fig 3). These assays can detect ≦1 ng HBsAg/ml serum or plasma. The solid phase may be a microtitre well, bead, cuvette or microcarrier, manufactured from polyvinyl, polycarbonate, polystyrene or nylon. Anti-HBs antibodies used in solid-phase capture immunoassays, both to capture HBsAg and to detect its capture, were originally polyclonal and had to be produced in two different species (such as horse and goat) to reduce cross-reactivity and non-specific binding. Polyclonal animal sera have been replaced in most assays by monoclonal antibodies of high specificity and affinity, directed against specific epitopes of HBsAg. In RIA, the detector antibody is labelled with a radioisotope. Iodine-125, which has a half-life of approximately 60 days, is the most commonly used isotopic label. Although RIAs combine high specificity and sensitivity, problems associated with the safe handling and disposal of radioactive materials.

**Laboratory techniques**

As HBV cannot be isolated with conventional cell culture techniques, serological and molecular biological methods have been applied for detecting HBV markers.

**Detection of HBsAg**

Techniques for detecting HBsAg are classified as first, second and third generation assays with first generation assays being the least sensitive. Agar gel diffusion, a first generation assay, is relatively insensitive and is now used mainly for characterising sub-type determinants of HBsAg. Although second generation assays such as counter immunoelectrophoresis and reverse passive latex agglutination are 5–10 times more sensitive than agar gel diffusion for detecting HBsAg they have been superseded by the more sensitive third generation assays. These assays which include reverse passive haemagglutination (RPH), radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA) and enhanced chemiluminescence are 50–100 times more sensitive than agar gel diffusion and are used in a majority of laboratories for detecting HBsAg.
Laboratory techniques in the diagnosis and assessment of hepatitis B virus infection

Figure 3 Immunoassays for detecting HBsAg.

Figure 4 Enzyme immunoassay for detecting HBsAg and anti-HBs.

as well as the short shelf-life of the radiolabelled antibody make them less attractive than ELISAs for the routine detection of HBsAg. ELISAs exhibit comparable sensitivity and specificity, use stable enzyme-labelled antibodies and have a comparatively long shelf-life.

ELISAs for detecting antigen can be made more sensitive by enzyme amplification. This may be achieved by allowing the bound enzyme to catalyse the formation of a colourless reaction product which in turn catalyses a colour-forming reaction. Alternatively, the avidin–biotin system, which makes use of the high affinity of avidin for biotin, can be used to increase the number of enzyme molecules bound and therefore produce a higher signal in the presence of enzyme substrate. In ELISAs which use enhanced chemiluminescence, emitted light may be detected in less than one minute compared to 20–30 minutes for a colour reaction to develop in a conventional ELISA.

The specificity of assays in current use will vary from manufacturer to manufacturer. In general, the specificity of enzyme immunoassays may depend on the condition of the specimen. Haemolysed serum/plasma or serum/plasma containing red blood cells or bacteria may contain endogenous enzymes which react with the enzyme substrate and produce false-positive reactions. Samples containing the preservative sodium azide, a potent peroxidase poison, may produce false-negative results in assays that use a peroxidase-labelled second antibody. Therefore, it is important to perform confirmatory tests on all reactive samples. Although this may be achieved by performing an alternative assay of similar sensitivity, a neutralisation test with anti-HBs is preferred.

Detection of HBeAg and anti-HBe

The detection of HBeAg and anti-HBe is usually accomplished in a single assay. The patient’s serum is added to two wells of a microtitre plate coated with anti-HBe monoclonal antibodies. Anti-HBe monoclonal antibody conjugated to horseradish peroxidase is added to the first well to detect HBeAg. To detect anti-HBe, HBeAg is added to the second well followed by the anti-HBe enzyme conjugate. Competition between anti-HBe present in the patient’s serum and the anti-HBe enzyme conjugate will result in a decrease in colour (fig 4).

Detection of anti-HBc

Anti-HBc may be the only serological marker present at certain times during the course of infection with HBV (fig 1). Anti-HBc can be detected when HBsAg is no longer detectable and anti-HBs has not yet reached detectable levels. This time is often referred to as the “core window”. Also, later in the course of HBV infection when both HBsAg and anti-HBs may not be detectable the only evidence of past infection is the presence of anti-HBc.

Anti-HBc, IgM, whose presence indicates active viral replication in the acute or chronic phases of HBV infection may be detected by means of a u-capture RIA or ELISA. Wells of a microtitre plate, coated with anti-human IgM (u-chain specific) are used to capture IgM from the patient’s serum. HBcAg is then added and will bind to any anti-HBc IgM present. Bound HBcAg can then be detected with a radio- or enzyme-labelled anti-HBc monoclonal antibody.

Total anti-HBc is usually detected in a competitive RIA or ELISA. Anti-HBc present in the patient’s serum and a radio- or enzyme-labelled anti-HBc compete for HBcAg bound to the solid phase. Therefore the proportion of conjugate bound to the HBcAg is inversely
Anti-HBs concentration (mIU/ml) | Response | Comment |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 100</td>
<td>Good</td>
<td>Booster dose recommended in 5 years*</td>
</tr>
<tr>
<td>10-100</td>
<td>Poor</td>
<td>Give a booster dose immediately and retest in 1–3 months</td>
</tr>
<tr>
<td>&lt; 10</td>
<td>None</td>
<td>Give a booster dose immediately and if no response in 1–3 months advise “not protected”. Consider another dose of vaccine and retest</td>
</tr>
</tbody>
</table>

*If vaccinees are monitored give booster dose when the concentration of anti-HBs falls below 10 mIU/ml.

**Detection of anti-HBs**
Assays to detect anti-HBs were initially used to indicate clearance of HBsAg in persons with previous HBV infection. However, since the introduction of HBV vaccines, these tests are used increasingly to demonstrate an immune response after vaccination with plasma-derived or recombinant HBV vaccines.

Seroconversion rates, after vaccination, vary between 80–100% in healthy adults and the persistence of anti-HBs is related to the peak antibody concentrations after vaccination. Therefore, any assay used to detect anti-HBs should be quantitative to allow vaccinees with an inadequate response as well as those who do not mount an immune response to be identified.

HBV infections, associated with escape mutants, have been reported in patients who had previously developed adequate levels of anti-HBs after vaccination. The viruses associated with these infections have a mutation in the highly antigenic “a” determinant of HBsAg.

The patient’s serum is added to a well of a microtitre plate coated with HBsAg and any bound anti-HBs detected with enzyme-labelled HBsAg conjugate. The concentration of the conjugate bound is directly proportional to the concentration of anti-HBs present in the serum sample. Results should be expressed as mIU/ml of anti-HBs and although the results of long-term follow-up studies on the duration of immunity following HBV vaccination are not yet available some basic guidelines are given in table 2.

**Automated systems**
The IMx system (Abbott Laboratories, USA) which is a fully automated immunoassay analyser is used to perform microparticle enzyme immunoassays (MEIA). These assays use submicron particles, coated with antigen or antibody, as their solid phase. After the addition of the sample all subsequent procedures are performed in an MEIA reaction cell which is constructed of the sample well, dilution and reaction wells and a well containing a glass fibre filter. Immune complexes formed during incubation of the patient’s serum with coated microparticles are captured on an inert glass fibre filter to which the microcarriers are transferred after incubation. Immune complexes are then detected with an alkaline phosphatase-labelled conjugate which catalyses the hydrolysis of 4-methyl umbelliferone phosphate to produce a fluorescent product, the intensity of which is measured in a fluorometer.

**HBV DNA and HBV DNA polymerase**
The presence of HBV DNA, detected in samples of serum by means of molecular biological techniques, is the most reliable marker of infectivity and virus replication in HBsAg chronic carriers. Although HBeAg is also used as a marker of viral replication it is not a reliable marker in patients infected with HBeAg minus mutants. The presence of serum HBV DNA in these patients is associated with persistence of viral replication. High concentrations of HBV DNA and low concentrations of alanine aminotransferase (ALT) are associated with minimal liver damage whereas low concentrations of HBV DNA in the presence of high concentrations of ALT are consistent with histologically apparent liver damage.

Nucleic acid hybridisation techniques for detecting HBV DNA use labelled complementary ssDNA to detect HBV DNA, rendered single stranded by denaturation and immobilised on nitrocellulose or nylon membranes (fig 5). HBV DNA may be obtained from the recombinant plasmid pBR 322-HBV, cloned in E coli, and purified from the plasmid by cleavage with the restriction enzyme XhoI followed by gel electrophoresis. The resulting DNA may be radiolabelled by “nick translation” or by random priming with the Multiprime DNA Labelling Kit (Amersham, UK) to produce a DNA probe with specific activities >10⁶ dpm/µg DNA.

Several methods for extracting HBV DNA from serum samples and performing the nucleic acid hybridisation assay have been described. Briefly, DNA is purified from serum samples by digestion with Pronase followed by extraction with phenol. The DNA,
collected from the aqueous phase, is then precipitated with absolute alcohol and re-suspended in a small volume of distilled water. The DNA samples are then applied to a nitrocellulose or nylon membrane, air dried, denatured and baked in a vacuum oven at 80°C. Non-specific binding of the probe DNA may be minimised by pre-hybridising at 70°C. The hybridisation mixture, containing the labelled probe DNA is heated to 100°C for 2–3 minutes to render the DNA single stranded before being added to the pre-hybridised membrane at 37°C. The membrane is incubated at 37°C overnight, washed to remove excess probe and autoradiographed at ~70°C.

HBV DNA hybridisation is capable of detecting 0.1 pg HBV DNA when the complementary DNA is labelled with the radioisotope P-32. Although biotinylated DNA probes do not suffer from the problems of short shelf-life and safe handling associated with radiolabelled probes, they may be less sensitive for detecting HBV DNA. Alternative non-radioactive probes such as those labelled with digoxigenin have been shown to be as sensitive as P-32 labelled probes for detecting HBV DNA.

**HBV DNA polymerase:** the presence of HBV DNA polymerase in the serum is an important marker of HBV replication and can be detected by its ability to synthesise DNA, incorporating a radiolabelled nucleotide, in vitro. The HBV DNA polymerase assay and the more sensitive HBV DNA hybridisation assay have been used to determine the efficacy of antiviral agents used in the treatment of HBV infection. The aim of antiviral chemotherapy is to disrupt viral replication by blocking viral polymerases more potently than cellular polymerases leading to the loss of HBcAg, HBV DNA and HBV DNA polymerase from the serum.

**The polymerase chain reaction**

The polymerase chain reaction (PCR) has been used by some researchers to detect HBV DNA in serum. This technique is used to amplify and make detectable low concentrations of HBV DNA undetectable by conventional nucleic acid hybridisation methods. Although PCR for detecting HBV DNA is not yet used widely, the increase in assay sensitivity and its ability to identify HBsAg carriers with a low level of viraemia may make it an exciting new tool for the laboratory diagnosis of HBV infection.

**Hepatitis D virus infection**

Hepatitis D virus (HDV) is an incomplete RNA virus that depends on HBV to replicate.


